Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like 45 years of progress: Prevention and screening avert millions of cancer deaths December 6, 2024 Step steady: Consistent walking improves brain function in older adults April 8, 2024 ‘Breaking a promise’: California deficit could halt raises for disability workers May 2, 2024